pharma · COVID-19 · Hepatitis C · AVIR
Atea Pharmaceuticals
Atea Pharmaceuticals is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker AVIR. Primary therapeutic focus areas include COVID-19, Hepatitis C, HEPATITIS C VIRUS CHRONIC INFECTION, Influen
225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US HQ
2014 Founded
57 Employees
Public company Type
AVIR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US
- Founded
- 2014
- Employees
- 57
- Programs
- 37
- Drugs
- 29
- Patents
- 35
AT-01B-008
Phase 3 · small molecule · Chronic Hepatitis C Virus (HCV) Infection
AT-01B-008 for Chronic Hepatitis C Virus (HCV) Infection is a Phase 3 program (small_molecule) at Atea Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code AT-01B-008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Atea Pharmaceuticals
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chronic Hepatitis C Virus (HCV) Infection
- Status
- active
- Trials
- 1